

# **Respiratory Medicines Optimisation Dashboard**

The Respiratory Medicines Optimisation
Dashboard highlights variations in respiratory
prescribing across CCGs in England. It also
gives you access to local level data to establish
your CCG's performance in this clinical area
and how it can be improved.



#### **Developed in collaboration**

The Dashboard was developed in collaboration with the National Respiratory Dashboard Task and Finish Group, utilising the rich source of prescribing data processed by the NHS Business Services Authority. The group comprises national respiratory specialists, who have agreed specific areas of focus with the aim of improving health outcomes for patients with respiratory conditions. These are represented in the dashboard as seven metrics, each with its own page view.

The Respiratory Medicines Optimisation Dashboard metrics:

- High dose ICS<sup>1</sup> items as a % of all ICS items: Identifying the level of high dose ICS prescribing for all ICS products.
- Inhaled steroid prevention (preventer therapy): Identifying the proportion of patients receiving 5 or fewer prescription items for ICS products, including ICS LABA<sup>2</sup>, within a rolling 12-month period.
- Prescribing of Montelukast: Identifying the level of prescribing for Montelukast, in relation to the number of patients identified on the asthma register.
- Prescribing frequency of Prednisolone 5mg tablets: Prescribing of Prednisolone 5mg tablets to patients, where quantity prescribed per item was less than or equal to 60 tablets. Results identify the total number of prescription items prescribed, with each item relating to a quantity of 60 tablets or fewer, and can be used as an indicator of the number of rescue packs issued per person.
- Prescribing of smoking cessation products: Identifying the prescribing of smoking cessation products, including nicotine replacement therapy (NRT) and varenicline and bupropion. Results identify the total number of prescription items prescribed for any smoking cessation product in relation to the recorded number of smokers.
- Excess SABA<sup>3</sup> prescribing: Results identify the total number of patients prescribed 6 or more SABA inhalers, who were also prescribed preventer inhaler but not prescribed antimuscarinic. Figures presented as a proportion of all patients prescribed a preventer inhaler without an antimuscarinic (to attempt to exclude COPD<sup>4</sup> patients).
- Patients on triple therapy: Results identify the total number of patients prescribed triple therapy, based on receiving LAMA<sup>5</sup>, LABA and ICS inhalers.

#### **Reviewing performance**

You can choose a reporting period for your CCG in each of the seven metrics and your performance will be displayed in the dashboard in a number of graphical presentations:

- Results for individual practices within the CCG this highlights the variation between practices.
- Results for CCGs in relation to other CCGs.
- Trend results showing the data across multiple time periods to allow trends to be identified.

You can search in more detail by selecting various grouping levels which will only display CCGs within the selected structure (i.e. Regions, STP Footprints, and AHSNs etc.)

#### **Accessing the Respiratory Dashboard**

The dashboard is available through our online application ePACT2. If you don't have access, and you wish to register for ePACT2, please email *nhsbsa.registration@nhs.net* 

### Tell us what you think

For the first iteration of the respiratory dashboard we have selected specific areas of prescribing based on the specialist opinion of the working group involved in its development. However we are planning to develop this dashboard further and welcome your ideas for the inclusion of other clinical areas in future iterations.

Our aim for the dashboard is to help you to deliver better outcomes for your patients so it is important that it works well for you. Please let us know about your experience of using the dashboard as well as any suggestions as this will help us to drive improvement. Please forward your feedback to: <a href="mailto:nhsbsa.informationsystems@nhs.net">nhsbsa.informationsystems@nhs.net</a>

## For further information please contact:



www.nhsbsa.nhs.uk/pacific



Twitter: @NhsbsaPacific

NHSBSA's Pacific Team is helping deliver sustainability for the NHS by identifying, developing and delivering opportunities which create financial savings for reinvestment back into the NHS, enhance health and wellbeing and improve the quality of patient care.

#### Glossary of terms:

<sup>1</sup>ICS - Inhaled Corticosteroid

<sup>2</sup>LABA - Long Acting Beta-<sup>2</sup> Agonist

<sup>3</sup>SABA - Short Acting Beta-<sup>2</sup> Agonist

<sup>4</sup>COPD – Chronic Obstructive Pulmonary Disease

<sup>5</sup>LAMA – Long Acting Muscarinic Antagonist